• Nenhum resultado encontrado

J. Pediatr. (Rio J.) vol.80 número6 en v80n6a15

N/A
N/A
Protected

Academic year: 2018

Share "J. Pediatr. (Rio J.) vol.80 número6 en v80n6a15"

Copied!
6
0
0

Texto

Loading

Imagem

Table 1  - Demographic characteristics of seven patients with macrophage activation syndrome (MAS) associated with juvenile idiopathic arthritis (JIA)

Referências

Documentos relacionados

We describe the clinical manifestations and physical capacity defi cits of patients with juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile systemic lupus

sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. Rituximab: mechanism

Macrophage activation syndrome (MAS) is a severe complication of rheumatic diseases that occurs much more frequently in patients with systemic juvenile idio- pathic arthritis

Erratum to “Effects of the use of growth hormone in children, adolescents with juvenile idiopathic arthritis: a systematic review”. (Rev

This table presents the results on the two-stage least squares estimation, for the analysis of the relation between incentive-aligned executive compensation and firm value

Objective: To measure and compare musculoskeletal pain in patients with juvenile fibromyalgia (JFM) and polyarticular juvenile idiopathic arthritis  (JIA), and to evaluate and

The serum IL-6 levels in various disease groups were all signi fi cantly higher than the healthy control group (P o 0.05), but the IL-6 concentration showed no signi fi - cant

Objective: To measure and compare musculoskeletal pain in patients with juvenile fibromyalgia (JFM) and polyarticular juvenile idiopathic arthritis  (JIA), and to evaluate and